MRVI vs. RARE, RNA, SWTX, ADMA, OGN, BHVN, PTCT, ALVO, SRRK, and ACLX
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), ADMA Biologics (ADMA), Organon & Co. (OGN), Biohaven (BHVN), PTC Therapeutics (PTCT), Alvotech (ALVO), Scholar Rock (SRRK), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.
Maravai LifeSciences vs.
Maravai LifeSciences (NASDAQ:MRVI) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.
Maravai LifeSciences currently has a consensus price target of $10.28, indicating a potential upside of 146.85%. Ultragenyx Pharmaceutical has a consensus price target of $92.43, indicating a potential upside of 120.54%. Given Maravai LifeSciences' higher probable upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Ultragenyx Pharmaceutical.
In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Maravai LifeSciences. MarketBeat recorded 15 mentions for Ultragenyx Pharmaceutical and 5 mentions for Maravai LifeSciences. Ultragenyx Pharmaceutical's average media sentiment score of 0.02 beat Maravai LifeSciences' score of -0.10 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.
Maravai LifeSciences has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Maravai LifeSciences has a net margin of -81.13% compared to Ultragenyx Pharmaceutical's net margin of -106.93%. Maravai LifeSciences' return on equity of -6.61% beat Ultragenyx Pharmaceutical's return on equity.
50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 0.6% of Maravai LifeSciences shares are held by company insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Maravai LifeSciences has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Ultragenyx Pharmaceutical received 772 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 77.44% of users gave Ultragenyx Pharmaceutical an outperform vote while only 62.63% of users gave Maravai LifeSciences an outperform vote.
Summary
Ultragenyx Pharmaceutical beats Maravai LifeSciences on 11 of the 18 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Maravai LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:MRVI) was last updated on 2/14/2025 by MarketBeat.com Staff